Vicus Capital’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $261K | Sell |
4,305
-82
| -2% | -$4.78K | 0.02% | 230 |
|
|
2025
Q4 | $237K | Buy |
+4,387
| New | +$211K | 0.02% | 239 |
|
|
2025
Q2 | – | Sell |
-4,000
| Closed | -$244K | – | 267 |
|
|
2025
Q1 | $244K | Buy |
4,000
+90
| +2% | +$5.25K | 0.02% | 212 |
|
|
2024
Q4 | $221K | Buy |
+3,910
| New | +$218K | 0.02% | 210 |
|
|
2024
Q3 | – | Sell |
-4,817
| Closed | -$200K | – | 238 |
|
|
2024
Q2 | $200K | Buy |
4,817
+944
| +24% | +$42.2K | 0.02% | 271 |
|
|
2024
Q1 | $210K | Buy |
+3,873
| New | +$197K | 0.02% | 258 |
|
|
2023
Q4 | – | Sell |
-4,824
| Closed | -$280K | – | 216 |
|
|
2023
Q3 | $280K | Buy |
4,824
+179
| +4% | +$11K | 0.03% | 207 |
|
|
2023
Q2 | $297K | Buy |
4,645
+885
| +24% | +$59.3K | 0.03% | 172 |
|
|
2023
Q1 | $261K | Buy |
3,760
+13
| +0.3% | +$917 | 0.03% | 177 |
|
|
2022
Q4 | $270K | Sell |
3,747
-76
| -2% | -$5.73K | 0.03% | 172 |
|
|
2022
Q3 | $272K | Sell |
3,823
-769
| -17% | -$55.8K | 0.03% | 176 |
|
|
2022
Q2 | $354K | Sell |
4,592
-2,343
| -34% | -$178K | 0.04% | 167 |
|
|
2022
Q1 | $506K | Sell |
6,935
-214
| -3% | -$14.4K | 0.05% | 146 |
|
|
2021
Q4 | $464K | Buy |
+7,149
| New | +$419K | 0.05% | 152 |
|
|
2021
Q2 | – | Sell |
-7,756
| Closed | -$490K | – | 164 |
|
|
2021
Q1 | $490K | Buy |
7,756
+137
| +2% | +$8.52K | 0.06% | 150 |
|
|
2020
Q4 | $473K | Sell |
7,619
-1,475
| -16% | -$90.7K | 0.06% | 140 |
|
|
2020
Q3 | $548K | Buy |
9,094
+1,008
| +12% | +$60.7K | 0.08% | 125 |
|
|
2020
Q2 | $475K | Buy |
8,086
+39
| +0.5% | +$2.33K | 0.07% | 124 |
|
|
2020
Q1 | $449K | Buy |
8,047
+1
| +0% | +$61 | 0.08% | 116 |
|
|
2019
Q4 | $516K | Buy |
8,046
+1,748
| +28% | +$100K | 0.08% | 124 |
|
|
2019
Q3 | $319K | Buy |
+6,298
| New | +$296K | 0.04% | 188 |
|
|
2017
Q4 | – | Sell |
-5,036
| Closed | -$321K | – | 230 |
|
|
2017
Q3 | $321K | Sell |
5,036
-1,156
| -19% | -$67.5K | 0.06% | 182 |
|
|
2017
Q2 | $345K | Buy |
6,192
+106
| +2% | +$5.77K | 0.07% | 169 |
|
|
2017
Q1 | $331K | Buy |
6,086
+139
| +2% | +$7.62K | 0.07% | 176 |
|
|
2016
Q4 | $348K | Sell |
5,947
-1,635
| -22% | -$89.4K | 0.08% | 166 |
|
|
2016
Q3 | $409K | Buy |
7,582
+1,558
| +26% | +$100K | 0.09% | 148 |
|
|
2016
Q2 | $443K | Buy |
6,024
+419
| +7% | +$29.6K | 0.11% | 126 |
|
|
2016
Q1 | $358K | Sell |
5,605
-5
| -0.1% | -$315 | 0.08% | 133 |
|
|
2015
Q4 | $386K | Sell |
5,610
-218
| -4% | -$14.4K | 0.1% | 133 |
|
|
2015
Q3 | $345K | Buy |
5,828
+55
| +1% | +$3.49K | 0.09% | 123 |
|
|
2015
Q2 | $384K | Buy |
5,773
+10
| +0.2% | +$659 | 0.1% | 125 |
|
|
2015
Q1 | $372 | Buy |
5,763
+153
| +3% | +$9.58K | 0.07% | 123 |
|
|
2014
Q4 | $331K | Sell |
5,610
-218
| -4% | -$12.3K | 0.1% | 121 |
|
|
2014
Q3 | $298K | Buy |
+5,828
| New | +$291K | 0.1% | 104 |
|
Other funds holding BMY
VCM
VPM
Vicus Capital's BMY Position: Q1 2026 in Review
Vicus Capital reduced its Bristol-Myers Squibb (BMY) stake by 1.9% in Q1 2026, selling an estimated $4.78K and leaving 4,305 shares worth $261K. The position accounts for 0.02% of the portfolio, ranked #230.
Vicus Capital first reported a position in BMY in Q3 2014 and has held it in 34 quarters since. The position peaked at $548K in Q3 2020. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Vicus Capital held 4,305 shares of Bristol-Myers Squibb worth $261K as of Q1 2026.
- Vicus Capital sold 82 Bristol-Myers Squibb shares in Q1 2026, an estimated $4.78K.
- Bristol-Myers Squibb made up 0.02% of Vicus Capital's portfolio in Q1 2026, its #230 holding.
- Vicus Capital first reported a position in Bristol-Myers Squibb in Q3 2014 and has held it in 34 quarters since.
- Vicus Capital's Bristol-Myers Squibb position peaked at $548K in Q3 2020.
- 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Vicus Capital's 13F filing for Q1 2026, filed 22 Apr 2026.